Sintanovo

Sintanovo is a biotechnology company focused on developing first-in-class small molecule therapeutics that target the SIN3 chromatin regulatory complex. The company's platform centers on disrupting the protein-protein interactions within the SIN3 complex, which plays a pivotal role in epigenetic regulation and the maintenance of cancer stem cell populations. By inhibiting SIN3, Sintanovo aims to reverse the transcriptional programs that drive tumor metastasis and drug resistance, particularly in aggressive cancers like triple-negative breast cancer. Currently in the preclinical stage, the company is advancing a pipeline of selective inhibitors designed to provide new treatment options for patients with high-risk solid tumors. Their approach represents a novel form of differentiation therapy that seeks to reprogram cancer cells into a less aggressive state.